Abstracts

Transmitted HIV Drug Resistance Among Early Infected Persons in San Diego, California

Background: Transmitted HIV drug resistance (TDR) continues to be an important issue, particularly for the initiation of antiretroviral therapy (ART). This study determined the prevalence and phylogenetic relationships of TDR among ART-naïve, HIV-infected individuals in San Diego County from 1996-2013. Methods: Retrospective analysis of the University of California, San Diego Primary Infection Resource Consortium from…

HIV Molecular Epidemiology and Transmitted Drug Resistance in the Mesoamerican Region

Background: Transmitted drug resistance (TDR) remains an important concern for the management of HIV infection, especially in countries that have recently scaled-up antiretroviral treatment (ART) access. We present preliminary results from a large study to assess HIV TDR and viral diversity in Mexico and Central America. Methods: HIV-infected ART-naïve individuals from Mexico (n=1476), Guatemala (n=1180),…

Increase in HIV Primary Drug Resistance in a Demographic Surveillance Area in Rural KwaZulu-Natal South Africa.

Background: Increased access to antiretroviral therapy (ART) has been associated with significant reductions in AIDS related morbidity and mortality as well as a significant reduction in HIV incidence. As more patients access ART, higher proportions of newly infected patients is expected to be infected with drug resistant viruses in resource limited settings. Methods: Samples from…

A Clinical Prediction Rule for PI Resistance in Resource-Limited Settings

Background: Although virological failure is common in adults on second-line ART in resource limited settings, major protease inhibitor (PI) resistance mutations occur infrequently. Therefore, empiric switches to salvage therapy would waste resources. Resistance testing identifies patients needing salvage therapy, but is expensive and access is limited. Therefore, a clinical prediction rule (CPR) to rationalise access…

Baseline Low-Frequency HIV-1 Variants Do Not Predict Virologic Failure to RPV/FTC/TDF

Background: Rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) is currently approved for use in HIV-1 treatment-naïve adults with HIV-1 RNA ≤100,000 c/mL due to increased virologic failure with resistance development in patients with high baseline viral load (BL VL). At Week 96 in the phase 3b STaR study (GS-US-264-0110; RPV/FTC/TDF vs. efavirenz/FTC/TDF in treatment-naïve adults with no BL VL…

High Prevalence of Genotypic Resistance to Integrase inhibitors of HIV-1 Strains in Taiwan

Background: Integrase inhibitor in combination with 2 nucleoside reverse-transcriptase inhibitors has been shown to be effective treatment options for antiretroviral(ARV)-naive HIV-1-infected patients. In Taiwan, raltegravir was first introduced in 2009 as a regimen of second line ARV and a pilot study by our laboratory in 2011 revealed that there was no HIV-1 strains harboring integrase…